| 16.04 0.14 (0.88%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 23.47 | 1-year : | 27.02 |
| Resists | First : | 20.09 | Second : | 23.13 |
| Pivot price | 17.62  |
|||
| Supports | First : | 15.18 | Second : | 12.62 |
| MAs | MA(5) : | 15.87 |
MA(20) : | 18.48 |
| MA(100) : | 18.18 |
MA(250) : | 18.15 |
|
| MACD | MACD : | -1.3 |
Signal : | -1 |
| %K %D | K(14,3) : | 11.9 |
D(3) : | 8.5 |
| RSI | RSI(14): 28.9 |
|||
| 52-week | High : | 28.79 | Low : | 11.82 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RGNX ] has closed above bottom band by 21.3%. Bollinger Bands are 11.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.42 - 16.5 | 16.5 - 16.57 |
| Low: | 15.41 - 15.5 | 15.5 - 15.58 |
| Close: | 15.89 - 16.04 | 16.04 - 16.17 |
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Tue, 23 Apr 2024
Raymond James & Associates Decreases Position in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
Wed, 17 Apr 2024
REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take ... - Yahoo Finance
Sun, 14 Apr 2024
Institutional owners may consider drastic measures as REGENXBIO Inc.'s (NASDAQ:RGNX) recent US$53m drop adds ... - Simply Wall St
Fri, 08 Mar 2024
Regenxbio Inc (RGNX) Chief Medical Officer Steve Pakola Sells 12,878 Shares - Yahoo Finance
Thu, 07 Mar 2024
Bearish: Analysts Just Cut Their REGENXBIO Inc. (NASDAQ:RGNX) Revenue and EPS estimates - Yahoo Finance
Wed, 06 Mar 2024
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study - Zacks Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 7.1 (%) |
| Held by Institutions | 81.7 (%) |
| Shares Short | 3,950 (K) |
| Shares Short P.Month | 3,830 (K) |
| EPS | -6.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.07 |
| Profit Margin | -292 % |
| Operating Margin | -271.1 % |
| Return on Assets (ttm) | -23.5 % |
| Return on Equity (ttm) | -63.7 % |
| Qtrly Rev. Growth | -29.2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.84 |
| EBITDA (p.s.) | -5.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -218 (M) |
| Levered Free Cash Flow | -134 (M) |
| PE Ratio | -2.67 |
| PEG Ratio | -0.3 |
| Price to Book value | 2.26 |
| Price to Sales | 8.71 |
| Price to Cash Flow | -3.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|